> Forum: Galapagos » Overzicht (kandidaat)medicijnen » Pagina: 4 | Beursonline.nl

Overzicht (kandidaat)medicijnen

66 Posts, Pagina: « 1 2 3 4 | Laatste
Lama Daila
2
Pokerface, we hebben een nieuw nummer: GLPG4716

GLPG4716
Lung diseases like IPF are associated with an increased chitinase activity, which strongly correlates with disease stage, progression and prognosis. Chitinases (predominantly CHIT1) are involved in macrophage activation. Inhibition of chitinase activity translates into a potential therapeutic benefit, as shown in a range of preclinical models. GLPG4716 has shown robust anti-fibrotic activity in multiple animal models, when compared with the standard of care.

GLPG4716 (formerly OATD-01 inlicensed from OncoArendi) is a novel, small molecule CHIT1/AMCase inhibitor targeting a key pathway in tissue remodeling. It has shown compelling translational data, a favorable profile in animal studies at expected therapeutic doses and it has successfully completed Phase 1 studies in healthy volunteers. Galapagos aims to bring GLPG4716 to a Phase 2 clinical trial for the treatment of IPF and possibly other diseases with a fibrotic component.
Lama Daila
1
quote:

Maycon schreef op 20 oktober 2020 16:30:


GLPG3667 = Plaque Psoriasis
clinicaltrials.gov/ct2/show/NCT04594928


Op de Toledo roundtable is gezegd dat Galapagos niet geïnteresseerd is in een middel tegen psoriasis omdat de unmet need daar niet zo groot meer is, maar psoriasis patiënten is wel een goede groep als signaalstudie in kleine fase1 studies.

Via het persbericht weten we nu dat het de bedoeling is dat GLPG3667 zal ingezet worden in PsA en UC:
“Pending successful completion of the Phase 1b study in psoriasis, we anticipate evaluating GLPG3667 in dose range finding Phase 2 studies in psoriatic arthritis and ulcerative colitis in the second half of 2021.“
de tuinman
0
quote:

Lama Daila schreef op 10 november 2020 08:37:


[...]

Op de Toledo roundtable is gezegd dat Galapagos niet geïnteresseerd is in een middel tegen psoriasis omdat de unmet need daar niet zo groot meer is, maar psoriasis patiënten is wel een goede groep als signaalstudie in kleine fase1 studies.

Via het persbericht weten we nu dat het de bedoeling is dat GLPG3667 zal ingezet worden in PsA en UC:
“Pending successful completion of the Phase 1b study in psoriasis, we anticipate evaluating GLPG3667 in dose range finding Phase 2 studies in psoriatic arthritis and ulcerative colitis in the second half of 2021.“



Psoriatic arthritis is a chronic disease characterized by a form of inflammation of the skin ( psoriasis) and joints (inflammatory arthritis )

holenbeer
0
quote:

Lama Daila schreef op 6 november 2020 13:44:


Pokerface, we hebben een nieuw nummer: GLPG4716

GLPG4716
Lung diseases like IPF are associated with an increased chitinase activity, which strongly correlates with disease stage, progression and prognosis. Chitinases (predominantly CHIT1) are involved in macrophage activation. Inhibition of chitinase activity translates into a potential therapeutic benefit, as shown in a range of preclinical models. GLPG4716 has shown robust anti-fibrotic activity in multiple animal models, when compared with the standard of care.

GLPG4716 (formerly OATD-01 inlicensed from OncoArendi) is a novel, small molecule CHIT1/AMCase inhibitor targeting a key pathway in tissue remodeling. It has shown compelling translational data, a favorable profile in animal studies at expected therapeutic doses and it has successfully completed Phase 1 studies in healthy volunteers. Galapagos aims to bring GLPG4716 to a Phase 2 clinical trial for the treatment of IPF and possibly other diseases with a fibrotic component.


Zou Gilead deze 'externe' moleculen ook mogen inlicenseren na succesvolle fase 2?
66 Posts, Pagina: « 1 2 3 4 | Laatste
Aantal posts per pagina:  20 50 100 | Omhoog ↑

Plaats een reactie

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Detail

Vertraagd 26 jan 2021 17:38
Koers 91,560
Verschil +0,620 (+0,68%)
Hoog 92,220
Laag 90,120
Volume 307.257
Volume gemiddeld 492.414
Volume gisteren 392.687